Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:pyridinemonocarboxylic acid
go back to main search page
Accession:CHEBI:26420 term browser browse the term
Definition:A monocarboxylic acid in which the carboxy group is attached to a pyridine (or substituted pyridine) ring.
Synonyms:related_synonym: pyridinemonocarboxylic acids
 cyclic_relationship: is_conjugate_acid_of CHEBI:38181


show annotations for term's descendants           Sort by:
 
1-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
JBrowse link
G Dek DEK proto-oncogene decreases chemical synthesis ISO DEK protein results in decreased chemical synthesis of N(1)-methylnicotinamide CTD PMID:28558019 NCBI chr17:17,965,872...17,987,836
Ensembl chr17:17,965,881...17,987,834
JBrowse link
G Lepr leptin receptor affects abundance ISO LEPR affects the abundance of N(1)-methylnicotinamide CTD PMID:20567778 NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] CTD PMID:32298659 NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression EXP N(1)-methylnicotinamide results in increased expression of PTGS2 mRNA CTD PMID:18385449 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Retn resistin multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of RETN mRNA] CTD PMID:32298659 NCBI chr12:2,201,909...2,203,649
Ensembl chr12:2,201,891...2,204,249
JBrowse link
G Slc22a1 solute carrier family 22 member 1 increases import ISO SLC22A1 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
JBrowse link
G Slc22a16 solute carrier family 22 member 16 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr20:45,658,398...45,669,192 JBrowse link
G Slc22a2 solute carrier family 22 member 2 increases import ISO SLC22A2 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
JBrowse link
G Slc22a3 solute carrier family 22 member 3 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] CTD PMID:10966924 NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
JBrowse link
4-pyridoxic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Col2a1 collagen type II alpha 1 chain multiple interactions EXP [COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pyridoxic Acid CTD PMID:24709313 NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
JBrowse link
6-aminonicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Fgf2 fibroblast growth factor 2 multiple interactions
increases expression
ISO IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of FGF2 protein] CTD PMID:12898533 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO 6-Aminonicotinamide inhibits the reaction [Fenretinide results in increased phosphorylation of GSK3B protein] CTD PMID:25246272 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO 6-Aminonicotinamide inhibits the reaction [arsenic trioxide results in increased expression of HMOX1 protein] CTD PMID:25246272 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
ISO IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of IL1B protein] CTD PMID:12898533 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
ISO 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT1 protein]; 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT2 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of FGF2 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of IL1B protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of NTF3 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TGFB1 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TNF protein]
6-Aminonicotinamide results in increased expression of IL6 protein
CTD PMID:12898533 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Mt1 metallothionein 1 multiple interactions
increases expression
decreases response to substance
ISO 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT1 protein]
6-Aminonicotinamide results in increased expression of MT1 protein
MT1 protein results in decreased susceptibility to 6-Aminonicotinamide
CTD PMID:11835189, PMID:12898533 NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
JBrowse link
G Mt2A metallothionein 2A multiple interactions
increases expression
decreases response to substance
ISO 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT2 protein]
6-Aminonicotinamide results in increased expression of MT2 protein
MT2 protein results in decreased susceptibility to 6-Aminonicotinamide
CTD PMID:11835189, PMID:12898533 NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
JBrowse link
G Mt3 metallothionein 3 increases expression ISO 6-Aminonicotinamide results in increased expression of MT3 protein CTD PMID:10785446 NCBI chr19:11,324,708...11,326,112
Ensembl chr19:11,324,698...11,326,139
JBrowse link
G Ntf3 neurotrophin 3 increases expression
multiple interactions
ISO 6-Aminonicotinamide results in increased expression of NTF3 protein
IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of NTF3 protein]
CTD PMID:12898533 NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO 6-Aminonicotinamide inhibits the reaction [arsenic trioxide results in increased cleavage of PARP1 protein] CTD PMID:25246272 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO 6-Aminonicotinamide results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:14,890,318...14,895,907
Ensembl chr 5:14,890,408...14,895,907
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases expression
ISO IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TGFB1 protein] CTD PMID:12898533 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
ISO 6-Aminonicotinamide results in increased expression of TNF protein
IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TNF protein]
CTD PMID:12898533 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
flunixin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgs1 prostaglandin-endoperoxide synthase 1 decreases activity EXP flunixin results in decreased activity of PTGS1 protein CTD PMID:12967936 NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
JBrowse link
imazamox term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO imazamox binds to and results in decreased activity of NR1H4 protein CTD PMID:21251949 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 affects activity ISO imazamox affects the activity of NR1I2 protein CTD PMID:23611293 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
imazapyr term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO imazapyr binds to and results in decreased activity of NR1H4 protein CTD PMID:21251949 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
isoniazide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin increases expression EXP Isoniazid results in increased expression of A2M mRNA CTD PMID:12883083 NCBI chr 4:154,309,426...154,359,138
Ensembl chr 4:154,309,426...154,359,137
JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions
decreases expression
EXP [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCB11 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCB11 mRNA] CTD PMID:25331106, PMID:32673658 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 increases expression EXP Isoniazid results in increased expression of ABCC1 mRNA CTD PMID:11752103 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
decreases expression
EXP [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCC2 mRNA
Isoniazid results in decreased expression of ABCC2 mRNA
CTD PMID:25331106, PMID:32673658 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions
decreases expression
EXP [Lipopolysaccharides co-treated with Isoniazid] results in increased expression of ABCC3 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCC3 mRNA] CTD PMID:25331106, PMID:32673658 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression EXP Isoniazid results in decreased expression of ABCC4 mRNA CTD PMID:32673658 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Abcc6 ATP binding cassette subfamily C member 6 decreases expression EXP Isoniazid results in decreased expression of ABCC6 mRNA CTD PMID:16260000 NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243
JBrowse link
G Afp alpha-fetoprotein decreases expression ISO Isoniazid results in decreased expression of AFP mRNA CTD PMID:30008028 NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
JBrowse link
G Agpat3 1-acylglycerol-3-phosphate O-acyltransferase 3 increases expression
multiple interactions
EXP Isoniazid results in increased expression of AGPAT3 mRNA
[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA]
CTD PMID:28619387 NCBI chr20:11,060,584...11,144,806
Ensembl chr20:11,114,164...11,144,806
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO Isoniazid results in increased expression of AKR1B10 mRNA CTD PMID:28444390 NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Alas1 5'-aminolevulinate synthase 1 increases expression ISO Isoniazid results in increased expression of ALAS1 protein CTD PMID:27438535, PMID:30517741 NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
JBrowse link
G Alb albumin affects binding ISO Isoniazid binds to ALB protein CTD PMID:25489718 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Apoa4 apolipoprotein A4 affects response to substance ISO APOA4 affects the susceptibility to Isoniazid CTD PMID:24848797 NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
JBrowse link
G Apoa5 apolipoprotein A5 multiple interactions
decreases expression
EXP [Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA]
Isoniazid results in decreased expression of APOA5 mRNA
CTD PMID:28619387 NCBI chr 8:50,559,079...50,561,720
Ensembl chr 8:50,559,126...50,561,736
JBrowse link
G App amyloid beta precursor protein increases expression ISO Isoniazid results in increased expression of APP mRNA CTD PMID:30008028 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Asl argininosuccinate lyase increases activity
multiple interactions
EXP Isoniazid results in increased activity of ASL protein
[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein]
CTD PMID:28619387 NCBI chr12:30,160,922...30,178,348
Ensembl chr12:30,165,694...30,178,341
JBrowse link
G Atp1b1 ATPase Na+/K+ transporting subunit beta 1 increases expression ISO Isoniazid results in increased expression of ATP1B1 mRNA CTD PMID:30008028 NCBI chr13:82,737,161...82,757,681
Ensembl chr13:82,737,159...82,758,004
JBrowse link
G Atp5f1b ATP synthase F1 subunit beta affects expression ISO Isoniazid affects the expression of ATP5B mRNA CTD PMID:24848797 NCBI chr 7:2,504,708...2,511,748
Ensembl chr 7:2,504,695...2,511,749
JBrowse link
G Atp5mc1 ATP synthase membrane subunit c locus 1 affects expression ISO Isoniazid affects the expression of ATP5G1 mRNA CTD PMID:24848797 NCBI chr10:83,895,941...83,898,640
Ensembl chr10:83,895,947...83,898,527
JBrowse link
G Atp5mc3 ATP synthase membrane subunit c locus 3 affects expression ISO Isoniazid affects the expression of ATP5G3 mRNA CTD PMID:24848797 NCBI chr 3:60,811,218...60,813,903
Ensembl chr 3:60,811,210...60,813,869
JBrowse link
G Atp5pb ATP synthase peripheral stalk-membrane subunit b affects expression ISO Isoniazid affects the expression of ATP5PB mRNA CTD PMID:24848797 NCBI chr 2:208,566,385...208,577,147
Ensembl chr 2:208,566,385...208,577,146
JBrowse link
G Atp5pf ATP synthase peripheral stalk subunit F6 affects expression ISO Isoniazid affects the expression of ATP5J mRNA CTD PMID:24848797 NCBI chr11:24,286,806...24,294,419
Ensembl chr11:24,286,787...24,294,179
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO [Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
Quercetin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
CTD PMID:21419764, PMID:31332904 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbox1 gamma-butyrobetaine hydroxylase 1 increases expression ISO Isoniazid results in increased expression of BBOX1 mRNA CTD PMID:30008028 NCBI chr 3:101,425,684...101,474,848
Ensembl chr 3:101,427,055...101,474,890
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
ISO [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]
Isoniazid results in decreased expression of BCL2 protein
Quercetin inhibits the reaction [Isoniazid results in decreased expression of BCL2 protein]
CTD PMID:21419764, PMID:31332904 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
ISO [Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
Isoniazid results in increased cleavage of CASP3 protein
acadesine promotes the reaction [Isoniazid results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP3 protein]
CTD PMID:21419764, PMID:23764483, PMID:28556920, PMID:31332904 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 increases cleavage
multiple interactions
ISO Isoniazid results in increased cleavage of CASP9 protein
Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP9 protein]
CTD PMID:31332904 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Casr calcium-sensing receptor affects expression EXP Isoniazid affects the expression of CASR mRNA CTD PMID:20623750 NCBI chr11:67,188,204...67,262,261
Ensembl chr11:67,188,630...67,258,771
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 decreases expression EXP Isoniazid results in decreased expression of CCR2 mRNA CTD PMID:20623750
G Cebpa CCAAT/enhancer binding protein alpha decreases expression ISO Isoniazid results in decreased expression of CEBPA mRNA; Isoniazid results in decreased expression of CEBPA protein CTD PMID:24128855 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta decreases expression ISO Isoniazid results in decreased expression of CEBPB protein CTD PMID:24128855 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta decreases expression ISO Isoniazid results in decreased expression of CEBPD mRNA; Isoniazid results in decreased expression of CEBPD protein CTD PMID:24128855 NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
JBrowse link
G Chpt1 choline phosphotransferase 1 affects response to substance ISO CHPT1 affects the susceptibility to Isoniazid CTD PMID:24848797 NCBI chr 7:29,019,518...29,070,928
Ensembl chr 7:29,043,916...29,070,928
JBrowse link
G Cldn2 claudin 2 increases expression ISO Isoniazid results in increased expression of CLDN2 mRNA CTD PMID:30008028 NCBI chr  X:111,122,552...111,133,188
Ensembl chr  X:111,122,552...111,137,769
JBrowse link
G Cox11 cytochrome c oxidase copper chaperone COX11 affects expression ISO Isoniazid affects the expression of COX11 mRNA CTD PMID:24848797 NCBI chr10:78,168,691...78,173,845
NCBI chr10:78,102,620...78,174,584
Ensembl chr10:78,111,050...78,174,584
JBrowse link
G Cox17 cytochrome c oxidase copper chaperone COX17 affects expression ISO Isoniazid affects the expression of COX17 mRNA CTD PMID:24848797 NCBI chr11:64,962,663...64,968,437
Ensembl chr11:64,962,666...64,968,437
JBrowse link
G Cox5b cytochrome c oxidase subunit 5B affects expression ISO Isoniazid affects the expression of COX5B mRNA CTD PMID:24848797 NCBI chr 9:43,259,706...43,262,039
Ensembl chr 9:43,259,709...43,262,040
JBrowse link
G Cox6a1 cytochrome c oxidase subunit 6A1 affects expression ISO Isoniazid affects the expression of COX6A1 mRNA CTD PMID:24848797 NCBI chr12:47,024,442...47,027,495
Ensembl chr12:47,024,442...47,027,495
JBrowse link
G Cox6b1 cytochrome c oxidase subunit 6B1 affects expression ISO Isoniazid affects the expression of COX6B1 mRNA CTD PMID:24848797 NCBI chr 1:89,075,987...89,084,834
Ensembl chr 1:89,075,975...89,084,859
Ensembl chr 2:89,075,975...89,084,859
JBrowse link
G Cox7a2 cytochrome c oxidase subunit 7A2 affects expression ISO Isoniazid affects the expression of COX7A2 mRNA CTD PMID:24848797 NCBI chr 8:87,209,529...87,213,627
Ensembl chr 8:87,209,530...87,213,627
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A affects expression ISO Isoniazid affects the expression of CPT1A mRNA CTD PMID:24848797 NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases secretion ISO Isoniazid results in increased secretion of CXCL10 protein CTD PMID:28444390 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions
decreases expression
EXP [Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA]
Isoniazid results in decreased expression of CYB5A mRNA
CTD PMID:28619387 NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 increases expression EXP Isoniazid results in increased expression of CYP27A1 mRNA CTD PMID:32673658 NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity
multiple interactions
ISO Isoniazid results in decreased activity of CYP2C8 protein
torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]
CTD PMID:15304522 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 affects response to substance
increases response to substance
multiple interactions
increases activity
increases expression
increases metabolic processing
ISO
EXP
CYP2E1 gene polymorphism affects the susceptibility to Isoniazid; CYP2E1 gene SNP affects the susceptibility to Isoniazid
CYP2E1 protein results in increased susceptibility to Isoniazid
GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]
Isoniazid results in increased activity of CYP2E1 protein
Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA]
Isoniazid results in increased expression of CYP2E1; Isoniazid results in increased expression of CYP2E1 mRNA; Isoniazid results in increased expression of CYP2E1 protein
2-(allylthio)pyrazine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Isoniazid results in increased activity of CYP2E1 protein] which results in increased metabolism of 4-dichlorobenzene; [Isoniazid results in increased expression of CYP2E1] which results in increased metabolism of Acetaminophen; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Isoniazid inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine]; Isoniazid results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; Thiram inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Tiopronin inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]
CYP2E1 protein results in increased metabolism of Isoniazid
CTD PMID:3113478, PMID:7710944, PMID:8074729, PMID:9051121, PMID:9065729, PMID:9129171, PMID:11752103, PMID:12458634, PMID:12668988, PMID:15132840, PMID:15205388, PMID:15763544, PMID:17950035, PMID:18754103, PMID:19683030, PMID:20485159, PMID:20566340, PMID:22342832, PMID:23211455, PMID:24929095, PMID:25683034, PMID:26880746, PMID:27919644, PMID:28762043 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; [SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] CTD PMID:19501153, PMID:27919644 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 increases expression
increases activity
multiple interactions
EXP Isoniazid results in increased expression of CYP3A23-3A1 mRNA
Isoniazid results in increased activity of CYP3A23-3A1 protein
diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP3A23-3A1 protein]
CTD PMID:12883083, PMID:26880746 NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
increases expression
EXP
ISO
[Lipopolysaccharides co-treated with Isoniazid] results in increased expression of CYP7A1 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in increased expression of CYP7A1 mRNA]
[Isoniazid co-treated with Vitamin B 6] results in increased expression of CYP7A1 mRNA
CTD PMID:25331106, PMID:32673658 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
decreases expression
EXP
ISO
Isoniazid results in increased expression of DDIT3 mRNA
Isoniazid results in decreased expression of DDIT3 mRNA
CTD PMID:12883083, PMID:30008028 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Depp1 DEPP1, autophagy regulator increases expression ISO Isoniazid results in increased expression of DEPP1 mRNA CTD PMID:17175557 NCBI chr 4:148,780,330...148,784,566
Ensembl chr 4:148,782,479...148,784,562
JBrowse link
G Epx eosinophil peroxidase increases oxidation
multiple interactions
ISO EPX protein results in increased oxidation of Isoniazid
[EPX protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD
CTD PMID:30922765 NCBI chr10:75,160,690...75,171,774
Ensembl chr10:75,160,690...75,171,774
JBrowse link
G Fech ferrochelatase decreases expression ISO Isoniazid results in decreased expression of FECH protein CTD PMID:27438535, PMID:30517741 NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha decreases expression EXP Isoniazid results in decreased expression of GADD45A mRNA CTD PMID:20623750 NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase increases expression EXP Isoniazid results in increased expression of GAPDH mRNA CTD PMID:12883083 NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
decreases expression
ISO Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of GCLC mRNA]
Isoniazid results in decreased expression of GCLC mRNA
CTD PMID:24128855 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit decreases expression ISO Isoniazid results in decreased expression of GCLM mRNA CTD PMID:30008028 NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions EXP [Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GGT1 protein CTD PMID:25331106 NCBI chr20:14,019,723...14,045,781
Ensembl chr20:14,019,723...14,025,068
JBrowse link
G Gpt glutamic--pyruvic transaminase increases activity
multiple interactions
increases expression
EXP
ISO
Isoniazid results in increased activity of GPT protein
Quercetin inhibits the reaction [Isoniazid results in increased expression of GPT protein]
[Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GPT protein; Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]; silybin inhibits the reaction [Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]]
CTD PMID:25331106, PMID:28619387, PMID:31332904 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression EXP Isoniazid results in increased expression of GSTA2 mRNA CTD PMID:12883083 NCBI chr 8:85,640,081...85,645,621 JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions
decreases response to substance
ISO GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]
GSTM1 protein results in decreased susceptibility to Isoniazid
CTD PMID:28762043 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstp1 glutathione S-transferase pi 1 decreases expression EXP Isoniazid results in decreased expression of GSTP1 mRNA CTD PMID:20623750 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
G Gstt1 glutathione S-transferase theta 1 multiple interactions ISO GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide] CTD PMID:18397238, PMID:20485159 NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 affects expression EXP Isoniazid affects the expression of HAVCR1 mRNA CTD PMID:20623750 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] CTD PMID:23764483 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression
ISO Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]
Isoniazid results in decreased expression of HMOX1 mRNA
CTD PMID:24128855 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hmox2 heme oxygenase 2 increases expression EXP Isoniazid results in increased expression of HMOX2 mRNA CTD PMID:12883083 NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
JBrowse link
G Hprt1 hypoxanthine phosphoribosyltransferase 1 increases expression EXP Isoniazid results in increased expression of HPRT1 mRNA CTD PMID:12883083 NCBI chr  X:158,196,640...158,228,815
Ensembl chr  X:158,197,149...158,228,749
JBrowse link
G Ifng interferon gamma increases secretion ISO Isoniazid results in increased secretion of IFNG protein CTD PMID:28444390 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il10 interleukin 10 increases secretion ISO Isoniazid results in increased secretion of IL10 protein CTD PMID:28444390 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il12a interleukin 12A increases secretion ISO Isoniazid results in increased secretion of IL12A protein CTD PMID:28444390 NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
JBrowse link
G Il12b interleukin 12B increases secretion ISO Isoniazid results in increased secretion of IL12B protein CTD PMID:28444390 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il17a interleukin 17A increases secretion ISO Isoniazid results in increased secretion of IL17A protein CTD PMID:28444390 NCBI chr 9:26,841,299...26,844,786
Ensembl chr 9:26,841,299...26,844,786
JBrowse link
G Il1a interleukin 1 alpha increases secretion ISO Isoniazid results in increased secretion of IL1A protein CTD PMID:28444390 NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
JBrowse link
G Il1b interleukin 1 beta increases secretion ISO Isoniazid results in increased secretion of IL1B protein CTD PMID:28444390 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Isoniazid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il6 interleukin 6 increases expression
increases secretion
ISO Isoniazid results in increased expression of IL6 protein
Isoniazid results in increased secretion of IL6 protein
CTD PMID:19575532, PMID:28444390 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Inhbe inhibin subunit beta E increases expression ISO Isoniazid results in increased expression of INHBE mRNA CTD PMID:17175557 NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169
JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 affects response to substance ISO LAMP1 affects the susceptibility to Isoniazid CTD PMID:24848797 NCBI chr16:81,689,576...81,714,341
Ensembl chr16:81,689,335...81,714,419
JBrowse link
G Lcn2 lipocalin 2 increases expression EXP Isoniazid results in increased expression of LCN2 mRNA CTD PMID:20623750 NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
JBrowse link
G LOC100912008 uncharacterized LOC100912008 affects expression ISO Isoniazid affects the expression of SURF1 mRNA CTD PMID:24848797 NCBI chr 3:4,869,790...4,872,633
Ensembl chr 3:4,869,795...4,872,632
JBrowse link
G Map2 microtubule-associated protein 2 affects expression ISO Isoniazid affects the expression of MAP2 mRNA CTD PMID:22131109 NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
multiple interactions
ISO Isoniazid results in decreased phosphorylation of MAPK1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]
CTD PMID:31332904 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein] CTD PMID:31332904 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mir106b microRNA 106b decreases expression EXP Isoniazide decreased expression of miR106b miRNA in the liver RGD PMID:29554950 RGD:15042854 NCBI chr12:19,307,752...19,307,833
Ensembl chr12:19,307,752...19,307,833
JBrowse link
G Mpo myeloperoxidase multiple interactions
increases oxidation
ISO [[MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals] which results in increased chemical synthesis of isonicotinyl-NAD; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD CTD PMID:26867495 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Mt-co3 mitochondrially encoded cytochrome c oxidase III increases expression EXP Isoniazid results in increased expression of COX3 mRNA CTD PMID:12883083 NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
JBrowse link
G Muc1 mucin 1, cell surface associated increases expression ISO Isoniazid results in increased expression of MUC1 mRNA CTD PMID:30008028 NCBI chr 2:188,543,137...188,547,874
Ensembl chr 2:188,543,137...188,547,874
JBrowse link
G Nat2 N-acetyltransferase 2 increases acetylation
multiple interactions
decreases expression
decreases acetylation
increases metabolic processing
affects metabolic processing
affects response to substance
ISO
EXP
NAT2 protein polymorphism results in increased acetylation of Isoniazid; NAT2 protein results in increased acetylation of Isoniazid
[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA]
Isoniazid results in decreased expression of NAT2 mRNA
[NAT2 gene polymorphism results in decreased acetylation of Isoniazid] which results in decreased abundance of acetylisoniazid; [NAT2 gene polymorphism results in decreased metabolism of Isoniazid] which results in increased abundance of hydrazine
NAT2 protein results in increased metabolism of Isoniazid
NAT2 protein affects the metabolism of Isoniazid; NAT2 protein polymorphism affects the metabolism of Isoniazid
NAT2 gene polymorphism affects the susceptibility to Isoniazid; NAT2 gene SNP affects the susceptibility to Isoniazid
CTD PMID:11379777, PMID:11915035, PMID:15546075, PMID:15565348, PMID:15618686, PMID:15627487, PMID:15908628, PMID:16531626, PMID:16847467, PMID:17509624, PMID:17973219, PMID:18544910, PMID:20485159, PMID:25794903, PMID:28619387, PMID:30358977 NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
JBrowse link
G Ncr3lg1 natural killer cell cytotoxicity receptor 3 ligand 1 increases expression ISO Isoniazid results in increased expression of NCR3LG1 mRNA; Isoniazid results in increased expression of NCR3LG1 protein CTD PMID:32060585 NCBI chr 1:102,078,274...102,093,495 JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 affects expression ISO Isoniazid affects the expression of NDUFA1 mRNA CTD PMID:24848797 NCBI chr  X:123,803,109...123,806,760
Ensembl chr  X:124,513,269...124,516,705
Ensembl chr  X:124,513,269...124,516,705
JBrowse link
G Ndufa10 NADH:ubiquinone oxidoreductase subunit A10 affects expression ISO Isoniazid affects the expression of NDUFA10 mRNA CTD PMID:24848797 NCBI chr 9:99,617,051...99,651,827
Ensembl chr 9:99,617,052...99,651,813
JBrowse link
G Ndufa12 NADH:ubiquinone oxidoreductase subunit A12 affects expression ISO Isoniazid affects the expression of NDUFA12 mRNA CTD PMID:24848797 NCBI chr 7:35,125,516...35,163,182
Ensembl chr 7:35,125,424...35,167,406
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 affects expression ISO Isoniazid affects the expression of NDUFA13 mRNA CTD PMID:24848797 NCBI chr16:21,275,311...21,282,246
Ensembl chr16:21,275,311...21,282,246
JBrowse link
G Ndufa4 NDUFA4, mitochondrial complex associated affects expression ISO Isoniazid affects the expression of NDUFA4 mRNA CTD PMID:24848797 NCBI chr 4:38,233,680...38,240,848
Ensembl chr 4:38,233,680...38,240,848
JBrowse link
G Ndufa5 NADH:ubiquinone oxidoreductase subunit A5 affects expression ISO Isoniazid affects the expression of NDUFA5 mRNA CTD PMID:24848797 NCBI chr 4:51,590,413...51,598,771
Ensembl chr 4:51,590,413...51,598,771
JBrowse link
G Ndufa8 NADH:ubiquinone oxidoreductase subunit A8 affects expression ISO Isoniazid affects the expression of NDUFA8 mRNA CTD PMID:24848797 NCBI chr 3:15,362,888...15,379,386
Ensembl chr 3:15,362,824...15,379,381
JBrowse link
G Ndufa9 NADH:ubiquinone oxidoreductase subunit A9 affects expression ISO Isoniazid affects the expression of NDUFA9 mRNA CTD PMID:24848797 NCBI chr 4:159,371,263...159,399,636
Ensembl chr 4:159,371,259...159,399,634
JBrowse link
G Ndufab1 NADH:ubiquinone oxidoreductase subunit AB1 affects expression ISO Isoniazid affects the expression of NDUFAB1 mRNA CTD PMID:24848797 NCBI chr 1:192,044,209...192,057,644
Ensembl chr 1:192,044,216...192,057,612
JBrowse link
G Ndufb10 NADH:ubiquinone oxidoreductase subunit B10 affects expression ISO Isoniazid affects the expression of NDUFB10 mRNA CTD PMID:24848797 NCBI chr10:14,090,128...14,092,289
Ensembl chr10:14,090,128...14,092,289
JBrowse link
G Ndufb2 NADH:ubiquinone oxidoreductase subunit B2 affects expression ISO Isoniazid affects the expression of NDUFB2 mRNA CTD PMID:24848797 NCBI chr 4:67,378,188...67,385,267
Ensembl chr 4:67,378,188...67,385,266
JBrowse link
G Ndufb3 NADH:ubiquinone oxidoreductase subunit B3 affects expression ISO Isoniazid affects the expression of NDUFB3 mRNA CTD PMID:24848797 NCBI chr 9:65,478,496...65,488,708
Ensembl chr 9:65,478,496...65,488,702
JBrowse link
G Ndufb5 NADH:ubiquinone oxidoreductase subunit B5 affects expression ISO Isoniazid affects the expression of NDUFB5 mRNA CTD PMID:24848797 NCBI chr 2:119,139,717...119,153,753
Ensembl chr 2:119,139,717...119,153,753
JBrowse link
G Ndufb6 NADH:ubiquinone oxidoreductase subunit B6 affects expression ISO Isoniazid affects the expression of NDUFB6 mRNA CTD PMID:24848797 NCBI chr 5:56,567,109...56,576,676
Ensembl chr 5:56,567,109...56,576,676
JBrowse link
G Ndufb7 NADH:ubiquinone oxidoreductase subunit B7 affects expression ISO Isoniazid affects the expression of NDUFB7 mRNA CTD PMID:24848797 NCBI chr19:24,701,067...24,705,405
Ensembl chr19:24,701,049...24,705,405
JBrowse link
G Ndufs1 NADH:ubiquinone oxidoreductase core subunit S1 affects expression ISO Isoniazid affects the expression of NDUFS1 mRNA CTD PMID:24848797 NCBI chr 9:69,919,863...69,953,182
Ensembl chr 9:69,919,867...69,953,182
JBrowse link
G Ndufs2 NADH:ubiquinone oxidoreductase core subunit S2 affects expression ISO Isoniazid affects the expression of NDUFS2 mRNA CTD PMID:24848797 NCBI chr13:89,606,848...89,623,506
Ensembl chr13:89,606,840...89,619,398
JBrowse link
G Ndufs3 NADH:ubiquinone oxidoreductase core subunit S3 affects expression ISO Isoniazid affects the expression of NDUFS3 mRNA CTD PMID:24848797 NCBI chr 3:79,721,686...79,728,863
Ensembl chr 3:79,721,694...79,728,879
JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 affects expression ISO Isoniazid affects the expression of NDUFS4 mRNA CTD PMID:24848797 NCBI chr 2:46,372,488...46,476,162
Ensembl chr 2:46,372,518...46,476,203
JBrowse link
G Ndufs8 NADH:ubiquinone oxidoreductase core subunit S8 affects expression ISO Isoniazid affects the expression of NDUFS8 mRNA CTD PMID:24848797 NCBI chr 1:219,141,289...219,144,610
Ensembl chr 1:219,141,292...219,144,610
JBrowse link
G Ndufv1 NADH:ubiquinone oxidoreductase core subunit V1 affects expression ISO Isoniazid affects the expression of NDUFV1 mRNA CTD PMID:24848797 NCBI chr 1:219,254,293...219,259,328
Ensembl chr 1:219,254,279...219,259,448
JBrowse link
G Ndufv2 NADH:ubiquinone oxidoreductase core subunit V2 affects expression ISO Isoniazid affects the expression of NDUFV2 mRNA CTD PMID:24848797 NCBI chr 9:113,875,718...113,900,169
Ensembl chr 9:113,875,703...113,900,190
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases activity ISO Isoniazid results in increased activity of NFE2L2 protein CTD PMID:30203046 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression
decreases expression
ISO Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]
Isoniazid results in increased expression of NQO1 mRNA
Isoniazid results in decreased expression of NQO1 mRNA
CTD PMID:24128855, PMID:28444390 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 decreases expression
multiple interactions
EXP
ISO
Isoniazid results in decreased expression of NR0B2 mRNA
[Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR0B2 mRNA
obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR0B2 mRNA]
CTD PMID:32673658 NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions
decreases expression
EXP
ISO
[Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 mRNA; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 protein; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR1H4 mRNA]
[Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR1H4 mRNA
isoniazide decreases expression of nr1h4 protein in rat liver
CTD PMID:25331106, PMID:32673658, PMID:30068870 RGD:15042870 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO Isoniazid results in increased activity of NR1I3 protein CTD PMID:30203046 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Nrf1 nuclear respiratory factor 1 multiple interactions
decreases expression
ISO acadesine inhibits the reaction [Isoniazid results in decreased expression of NRF1 protein] CTD PMID:28556920 NCBI chr 4:57,335,732...57,445,317
Ensembl chr 4:57,378,069...57,445,341
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator increases expression ISO Isoniazid results in increased expression of NUPR1 mRNA CTD PMID:17175557 NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
JBrowse link
G Ogdh oxoglutarate dehydrogenase affects expression ISO Isoniazid affects the expression of OGDH mRNA CTD PMID:24848797 NCBI chr14:86,414,924...86,481,903
Ensembl chr14:86,414,949...86,613,327
JBrowse link
G Park7 Parkinsonism associated deglycase affects expression ISO Isoniazid affects the expression of PARK7 mRNA CTD PMID:24848797 NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
JBrowse link
G Plod2 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 increases expression ISO Isoniazid results in increased expression of PLOD2 mRNA CTD PMID:15997088 NCBI chr 8:99,977,334...100,059,736
Ensembl chr 8:99,977,334...100,059,736
JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions
decreases expression
EXP [Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA]
Isoniazid results in decreased expression of POR mRNA
CTD PMID:28619387 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases activity ISO Isoniazid results in increased activity of PPARA protein CTD PMID:30203046 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases expression ISO Isoniazid results in decreased expression of PPARG mRNA
Isoniazid results in decreased expression of PPARG mRNA; Isoniazid results in decreased expression of PPARG protein
CTD PMID:24128855 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha decreases expression
multiple interactions
ISO Isoniazid results in decreased expression of PPARGC1A protein
acadesine inhibits the reaction [Isoniazid results in decreased expression of PPARGC1A protein]
CTD PMID:28556920 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Psen1 presenilin 1 affects expression ISO Isoniazid affects the expression of PSEN1 mRNA CTD PMID:24848797 NCBI chr 6:107,169,514...107,221,000
Ensembl chr 6:107,169,528...107,216,798
JBrowse link
G Sdha succinate dehydrogenase complex flavoprotein subunit A affects expression ISO Isoniazid affects the expression of SDHA mRNA CTD PMID:24848797 NCBI chr 1:31,545,631...31,570,601
Ensembl chr 1:31,545,631...31,570,601
JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B affects expression ISO Isoniazid affects the expression of SDHB mRNA CTD PMID:24848797 NCBI chr 5:159,484,378...159,505,063
Ensembl chr 5:159,484,370...159,505,064
JBrowse link
G Sdhd succinate dehydrogenase complex subunit D affects expression ISO Isoniazid affects the expression of SDHD mRNA CTD PMID:24848797 NCBI chr 8:55,028,125...55,037,604
Ensembl chr 8:55,028,125...55,037,604
JBrowse link
G Sfn stratifin decreases expression ISO Isoniazid results in decreased expression of SFN mRNA CTD PMID:30008028 NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
ISO acadesine inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]; Quercetin inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein] CTD PMID:28556920, PMID:31332904 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Slc10a1 solute carrier family 10 member 1 decreases expression
multiple interactions
EXP Isoniazid results in decreased expression of SLC10A1 mRNA
obeticholic acid promotes the reaction [Isoniazid results in decreased expression of SLC10A1 mRNA]
CTD PMID:32673658 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
G Slc11a1 solute carrier family 11 member 1 affects expression EXP Isoniazid affects the expression of SLC11A1 mRNA CTD PMID:20623750 NCBI chr 9:81,655,590...81,666,697
Ensembl chr 9:81,655,629...81,666,706
JBrowse link
G Slc7a5 solute carrier family 7 member 5 decreases expression ISO Isoniazid results in decreased expression of SLC7A5 mRNA CTD PMID:30008028 NCBI chr19:54,693,959...54,722,563
Ensembl chr19:54,693,959...54,722,563
JBrowse link
G Slco1a1 solute carrier organic anion transporter family, member 1a1 decreases expression EXP Isoniazid results in decreased expression of SLCO1B1 mRNA CTD PMID:32673658 NCBI chr 4:176,158,174...176,231,331
Ensembl chr 4:176,158,640...176,231,344
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
affects expression
EXP
ISO
[SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid
Isoniazid affects the expression of SOD2 mRNA
CTD PMID:19501153, PMID:24848797 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Spp1 secreted phosphoprotein 1 affects expression
decreases expression
EXP
ISO
Isoniazid affects the expression of SPP1 mRNA
Isoniazid results in decreased expression of SPP1 mRNA
CTD PMID:20623750, PMID:30008028 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Srxn1 sulfiredoxin 1 increases expression ISO Isoniazid results in increased expression of SRXN1 mRNA CTD PMID:28444390 NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
JBrowse link
G Surf1 SURF1, cytochrome c oxidase assembly factor affects expression ISO Isoniazid affects the expression of SURF1 mRNA CTD PMID:24848797 NCBI chr 3:5,461,717...5,464,560
Ensembl chr 3:4,869,795...4,872,632
JBrowse link
G Tf transferrin increases expression EXP Isoniazid results in increased expression of TF mRNA CTD PMID:12883083 NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
increases secretion
EXP
ISO
Isoniazid results in increased expression of TNF protein
[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein; Isoniazid promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein]
Isoniazid results in increased secretion of TNF protein
CTD PMID:25331106, PMID:28444390, PMID:28619387 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tpo thyroid peroxidase decreases activity EXP Isoniazid results in decreased activity of TPO protein CTD PMID:26884060 NCBI chr 6:49,020,918...49,089,855
Ensembl chr 6:49,021,044...49,089,855
JBrowse link
G Trak1 trafficking kinesin protein 1 affects expression ISO Isoniazid affects the expression of TRAK1 mRNA CTD PMID:24848797 NCBI chr 8:129,946,596...130,106,382
Ensembl chr 8:130,009,573...130,106,382
JBrowse link
G Trib3 tribbles pseudokinase 3 increases expression ISO Isoniazid results in increased expression of TRIB3 mRNA CTD PMID:30008028 NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
JBrowse link
G Txn2 thioredoxin 2 affects expression ISO Isoniazid affects the expression of TXN2 mRNA CTD PMID:24848797 NCBI chr 7:119,144,350...119,158,173
Ensembl chr 7:119,144,351...119,158,201
JBrowse link
G Txnrd1 thioredoxin reductase 1 increases expression ISO Isoniazid results in increased expression of TXNRD1 mRNA CTD PMID:28444390 NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
JBrowse link
G Txnrd2 thioredoxin reductase 2 affects expression ISO Isoniazid affects the expression of TXNRD2 mRNA CTD PMID:24848797 NCBI chr11:86,667,994...86,716,063
Ensembl chr11:86,667,997...86,716,254
JBrowse link
G Uqcrb ubiquinol-cytochrome c reductase binding protein affects expression ISO Isoniazid affects the expression of UQCRB mRNA CTD PMID:24848797 NCBI chr 7:71,264,501...71,269,869
Ensembl chr 7:71,264,514...71,269,869
Ensembl chr 1:71,264,514...71,269,869
JBrowse link
G Uqcrc2 ubiquinol cytochrome c reductase core protein 2 affects expression ISO Isoniazid affects the expression of UQCRC2 mRNA CTD PMID:24848797 NCBI chr 1:190,555,177...190,585,741
Ensembl chr 1:190,555,177...190,585,734
JBrowse link
isonicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bglap bone gamma-carboxyglutamate protein increases expression EXP
ISO
isonicotinamide results in increased expression of BGLAP mRNA CTD PMID:16813520, PMID:21745208 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Fabp4 fatty acid binding protein 4 decreases expression
increases expression
ISO isonicotinamide results in decreased expression of FABP4 mRNA
isonicotinamide results in increased expression of FABP4 mRNA
CTD PMID:16813520 NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases expression ISO isonicotinamide results in decreased expression of PPARG mRNA CTD PMID:16813520 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Runx2 RUNX family transcription factor 2 increases expression ISO isonicotinamide results in increased expression of RUNX2 mRNA CTD PMID:21745208 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Sirt1 sirtuin 1 increases activity
increases expression
ISO isonicotinamide results in increased activity of SIRT1 protein
isonicotinamide results in increased expression of SIRT1 mRNA
CTD PMID:21745208 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Sp7 Sp7 transcription factor increases expression ISO isonicotinamide results in increased expression of SP7 mRNA CTD PMID:21745208 NCBI chr 7:143,957,316...143,967,488
Ensembl chr 7:143,958,858...143,967,484
JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression ISO isonicotinamide results in increased expression of SPP1 mRNA CTD PMID:21745208 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B increases expression ISO isonicotinamide results in increased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
JBrowse link
N'-acetylisoniazid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mpo myeloperoxidase increases oxidation ISO MPO protein results in increased oxidation of (N)1-acetylisoniazid CTD PMID:26867495 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
N-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of N-methylnicotinamide
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide]
CTD PMID:27469509 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of N-methylnicotinamide CTD PMID:21561886 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
N-ribosylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions ISO nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] CTD PMID:25440059 NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions
increases oxidation
ISO [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite
CTD PMID:20399199, PMID:29281794 NCBI chr17:32,131,847...32,158,559
Ensembl chr17:32,132,347...32,158,538
JBrowse link
nicorandil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc9 ATP binding cassette subfamily C member 9 increases activity ISO Nicorandil results in increased activity of ABCC9 protein CTD PMID:22622455 NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
JBrowse link
G Agt angiotensinogen multiple interactions ISO Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] CTD PMID:22622455 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein] CTD PMID:31376360 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] CTD PMID:31376360 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Cat catalase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein] CTD PMID:31376360 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ctsd cathepsin D multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] CTD PMID:11829124, PMID:14499179 NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
JBrowse link
G Gal galanin and GMAP prepropeptide multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] CTD PMID:11829124, PMID:14499179 NCBI chr 1:218,653,059...218,657,922
Ensembl chr 1:218,652,917...218,657,925
JBrowse link
G Gusb glucuronidase, beta multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] CTD PMID:11829124, PMID:14499179 NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:31376360 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression EXP Nicorandil results in decreased expression of HMOX1 protein CTD PMID:22622455 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] CTD PMID:31376360 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein] CTD PMID:31376360 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] CTD PMID:31376360 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein] CTD PMID:31376360 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP Nicorandil results in increased expression of SOD2 protein CTD PMID:22622455 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein] CTD PMID:31376360 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein] CTD PMID:31376360 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions
decreases expression
ISO
EXP
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein]
Nicorandil results in decreased expression of XDH protein
CTD PMID:22622455 NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
JBrowse link
nicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions
decreases phosphorylation
ISO
EXP
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]
Niacinamide results in decreased phosphorylation of ACACA protein
CTD PMID:18482975, PMID:19071085, PMID:21212096 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases secretion
multiple interactions
ISO
EXP
Niacinamide results in increased secretion of ADIPOQ protein
[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]
CTD PMID:17452443, PMID:21439372 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
JBrowse link
G Ago2 argonaute RISC catalytic component 2 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein] CTD PMID:24792773 NCBI chr 7:114,339,607...114,377,277
Ensembl chr 7:114,339,434...114,380,613
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA CTD PMID:18420994 NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein] CTD PMID:25478867 NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
EXP
ISO
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX mRNA]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX protein]
[Berberine co-treated with Niacinamide] results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]
Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein
CTD PMID:16168987, PMID:16998810, PMID:22164206, PMID:25478867, PMID:26712469 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA
Niacinamide results in increased expression of BBC3 mRNA
CTD PMID:26712469 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]
CTD PMID:25472572, PMID:25478867, PMID:26712469 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein]
Niacinamide results in increased expression of BCL2L11 mRNA
CTD PMID:25472572, PMID:26712469 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein] CTD PMID:24792773 NCBI chr17:85,360,439...85,370,283
Ensembl chr17:85,364,483...85,368,208
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased activity of CASP3 protein]
Niacinamide results in increased cleavage of CASP3 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
CTD PMID:16505238, PMID:22164206, PMID:24040102, PMID:24962570, PMID:25478867, PMID:26712469 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]
CTD PMID:16505238, PMID:25478867, PMID:26712469 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase multiple interactions EXP [Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] CTD PMID:20307516, PMID:21382363, PMID:21439372, PMID:21630391, PMID:22056647, PMID:23677724, PMID:29247773 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Niacinamide results in decreased expression of CCL2 protein CTD PMID:14627904 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 increases expression ISO Niacinamide results in increased expression of CCL20 mRNA CTD PMID:22385246 NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
JBrowse link
G Cd40 CD40 molecule multiple interactions ISO Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] CTD PMID:22717288 NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
decreases expression
ISO
EXP
Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]
Niacinamide results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]
Niacinamide results in decreased expression of CDKN1A protein
CTD PMID:12782109, PMID:22561310, PMID:25478867 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression
multiple interactions
EXP Niacinamide results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
CTD PMID:22561310 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter] CTD PMID:24792773 NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases activity
multiple interactions
ISO Niacinamide results in increased activity of CHUK protein
resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]
CTD PMID:24962570 NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of COL1A1 mRNA
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]
CTD PMID:16813520, PMID:25707573 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions
increases expression
EXP Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA] CTD PMID:23422569 NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] CTD PMID:27919644 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] CTD PMID:27919644 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Defb4 defensin beta 4 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA CTD PMID:24894820 NCBI chr16:75,634,598...75,637,789
Ensembl chr16:75,634,598...75,637,789
JBrowse link
G Dicer1 dicer 1 ribonuclease III multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein] CTD PMID:24792773 NCBI chr 6:128,388,084...128,453,234
Ensembl chr 6:128,388,053...128,434,183
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA] CTD PMID:21232033 NCBI chr11:72,164,566...72,378,895
Ensembl chr11:72,163,749...72,378,895
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein] CTD PMID:24792773 NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of EIF4EBP1 protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein]
CTD PMID:19928762, PMID:20169165 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor increases abundance
multiple interactions
ISO ERCC6 gene mutant form results in increased abundance of Niacinamide
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]
CTD PMID:25440059 NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
JBrowse link
G F3 coagulation factor III, tissue factor decreases expression ISO Niacinamide results in decreased expression of F3 protein CTD PMID:14627904 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein] CTD PMID:16168987 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO
EXP
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein
Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]
CTD PMID:16917544, PMID:20181797, PMID:26712469 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein CTD PMID:23022493, PMID:25472572, PMID:26712469 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
G G6pc glucose-6-phosphatase, catalytic subunit multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA] CTD PMID:16917544 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein] CTD PMID:19059388 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gcg glucagon multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA] CTD PMID:23466488 NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein] CTD PMID:21439372 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
increases expression
EXP Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Niacinamide results in increased expression of GLB1 protein
CTD PMID:22561310 NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
JBrowse link
G Glo1 glyoxalase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein] CTD PMID:21439372 NCBI chr20:9,273,589...9,291,608
Ensembl chr20:9,273,594...9,291,610
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein] CTD PMID:20307516, PMID:21439372 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA] CTD PMID:21439372 NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
JBrowse link
G Gys2 glycogen synthase 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein] CTD PMID:19059388 NCBI chr 4:176,638,632...176,679,805
Ensembl chr 4:176,638,629...176,679,815
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein] CTD PMID:19647726 NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
JBrowse link
G Hdac1 histone deacetylase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein] CTD PMID:24792773 NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] CTD PMID:20696151, PMID:21212096 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein] CTD PMID:21439372 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] CTD PMID:24145604 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA CTD PMID:29594315 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] CTD PMID:16917544 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]
Niacinamide results in decreased expression of IL1B mRNA
Niacinamide results in increased expression of IL1B mRNA
CTD PMID:20307516, PMID:21439372, PMID:22385246, PMID:29594315 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of IL6 protein
[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]
CTD PMID:12727023, PMID:20307516, PMID:21439372 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ins2 insulin 2 multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein] CTD PMID:16168987 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein] CTD PMID:21439372 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] CTD PMID:20696151 NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] CTD PMID:20696151 NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] CTD PMID:16505238 NCBI chr 7:116,779,368...116,781,815
Ensembl chr 7:116,780,681...116,781,766
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form] CTD PMID:24145604 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein] CTD PMID:16168987 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO Niacinamide results in increased expression of MDM2 mRNA CTD PMID:16998810 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Mir3545 microRNA 3545 multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter] CTD PMID:24792773 NCBI chr 6:136,704,947...136,705,061
Ensembl chr 6:136,704,947...136,705,061
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
ISO Niacinamide results in increased expression of MMP9 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]
CTD PMID:24145604, PMID:24962570 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Msra methionine sulfoxide reductase A multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein] CTD PMID:23022493 NCBI chr15:47,488,333...47,800,662
Ensembl chr15:47,488,894...47,800,024
JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of MTOR protein
Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]
CTD PMID:19928762 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein] CTD PMID:22028816, PMID:24792773 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nabp2 nucleic acid binding protein 2 decreases ubiquitination
increases acetylation
multiple interactions
ISO Niacinamide results in decreased ubiquitination of NABP2 protein
Niacinamide results in increased acetylation of NABP2 protein
Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]
CTD PMID:26170237 NCBI chr 7:2,820,006...2,825,627
Ensembl chr 7:2,820,007...2,825,608
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of NAMPT protein
Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein
CTD PMID:26712469, PMID:32298659 NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
JBrowse link
G Ncor1 nuclear receptor co-repressor 1 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of NCOR1 protein
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]
CTD PMID:22539994 NCBI chr10:48,629,121...48,772,890
Ensembl chr10:48,629,121...48,772,890
JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA] CTD PMID:23891692 NCBI chr  X:123,803,109...123,806,760
Ensembl chr  X:124,513,269...124,516,705
Ensembl chr  X:124,513,269...124,516,705
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein] CTD PMID:23891692 NCBI chr16:21,275,311...21,282,246
Ensembl chr16:21,275,311...21,282,246
JBrowse link
G Ndufa2 NADH:ubiquinone oxidoreductase subunit A2 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA] CTD PMID:23891692 NCBI chr18:29,585,671...29,587,760
Ensembl chr18:29,585,671...29,587,760
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein] CTD PMID:21439372 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein] CTD PMID:23735732 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
EXP GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA] CTD PMID:23422569 NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions ISO [Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA CTD PMID:20505214 NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
JBrowse link
G Ogdh oxoglutarate dehydrogenase multiple interactions ISO Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein] CTD PMID:18381761 NCBI chr14:86,414,924...86,481,903
Ensembl chr14:86,414,949...86,613,327
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
decreases activity
EXP
ISO
Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased cleavage of PARP1 protein]
Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein
Niacinamide results in increased cleavage of PARP1 protein
Niacinamide results in decreased activity of PARP1 protein
CTD PMID:16168987, PMID:19288225, PMID:22164206, PMID:26712469, PMID:29143419 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein] CTD PMID:20181797 NCBI chr 4:30,546,772...30,556,774
Ensembl chr 4:30,546,664...30,556,814
JBrowse link
G Pdp1 pyruvate dehyrogenase phosphatase catalytic subunit 1 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein] CTD PMID:20181797 NCBI chr 5:25,577,593...25,584,325
Ensembl chr 5:25,577,451...25,584,288
JBrowse link
G Pitx2 paired-like homeodomain 2 increases expression ISO Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein CTD PMID:29143419 NCBI chr 2:233,602,732...233,621,059
Ensembl chr 2:233,602,732...233,621,129
JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions ISO Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein] CTD PMID:22028816 NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein] CTD PMID:22539994 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases acetylation
multiple interactions
ISO
EXP
Niacinamide results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]
CTD PMID:19071085, PMID:23422569, PMID:23891692 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein] CTD PMID:18482975 NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein] CTD PMID:18482975 NCBI chr 5:124,568,845...124,642,569
Ensembl chr 5:124,574,079...124,642,569
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Niacinamide results in increased expression of PTGS2 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]
CTD PMID:24145604, PMID:24962570 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Pygl glycogen phosphorylase L multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 NCBI chr 6:92,597,759...92,643,734
Ensembl chr 6:92,597,706...92,643,847
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]
Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein]
Niacinamide inhibits the reaction [resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]
CTD PMID:20307516, PMID:21439372, PMID:22717288, PMID:23406761, PMID:23735732, PMID:24962570, PMID:25108154 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein CTD PMID:20169165 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression
multiple interactions
increases expression
ISO
EXP
Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein
resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]
Niacinamide results in increased expression of RUNX2 mRNA
CTD PMID:16813520, PMID:22539994 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions
increases expression
ISO Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]
Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein
CTD PMID:21778425, PMID:24557422 NCBI chr 2:188,745,503...188,757,066
Ensembl chr 2:188,745,503...188,757,066
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
decreases activity
ISO
EXP
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]
Niacinamide results in decreased expression of SIRT1 protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]
Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
CTD PMID:16366736, PMID:17103016, PMID:18420994, PMID:18482975, PMID:18681908, PMID:19071085, PMID:19288225, PMID:19664641, PMID:19928762, PMID:20169165, PMID:20181797, PMID:21212096, PMID:21232033, PMID:21745208, PMID:21892612, PMID:22385246, PMID:22561310, PMID:22990594, PMID:23211629, PMID:23422569, PMID:23479127, PMID:23735732, PMID:23891692, PMID:24557422, PMID:24894820, PMID:25108154, PMID:25472572, PMID:25517228, PMID:26712469, PMID:28973641 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Sirt2 sirtuin 2 decreases activity
multiple interactions
ISO Niacinamide results in decreased activity of SIRT2 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein
CTD PMID:17341628, PMID:26712469 NCBI chr 1:86,948,866...86,971,954
Ensembl chr 1:86,948,918...86,971,952
JBrowse link
G Sirt3 sirtuin 3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein CTD PMID:26712469 NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA] CTD PMID:32298659 NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of Niacinamide CTD PMID:21561886 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
G Snap23 synaptosome associated protein 23 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA] CTD PMID:25999625 NCBI chr 3:112,333,972...112,362,960 JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]
Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]
CTD PMID:23891692, PMID:25472572 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sox9 SRY-box transcription factor 9 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of SOX9 protein
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]
CTD PMID:24962570 NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]] CTD PMID:23319015 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Stx4 syntaxin 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA] CTD PMID:25999625 NCBI chr 1:199,287,384...199,295,606
Ensembl chr 1:199,287,710...199,294,979
JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]
Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
Niacinamide results in increased expression of TNF mRNA
CTD PMID:20307516, PMID:21439372, PMID:22385246, PMID:22717288, PMID:24145604 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B decreases expression ISO Niacinamide results in decreased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
JBrowse link
G Tnfsf11 TNF superfamily member 11 decreases expression ISO Niacinamide results in decreased expression of TNFSF11 mRNA CTD PMID:16813520 NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]
Niacinamide results in decreased expression of TP53 protein
CTD PMID:12782109, PMID:18482975, PMID:18681908, PMID:25478867, PMID:26712469 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Ucp2 uncoupling protein 2 multiple interactions ISO Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] CTD PMID:16366736 NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
JBrowse link
G Vamp2 vesicle-associated membrane protein 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA] CTD PMID:25999625 NCBI chr10:55,675,171...55,679,405
Ensembl chr10:55,675,575...55,679,450
JBrowse link
nicotinic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions
increases expression
decreases expression
ISO
EXP
[Chromium co-treated with Niacin] results in decreased expression of ABCA1 mRNA
Niacin results in increased expression of ABCA1 mRNA
Niacin results in decreased expression of ABCA1 protein
2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin results in increased expression of ABCA1 mRNA]; [[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein; ABCA1 protein promotes the reaction [Niacin results in increased export of Cholesterol, HDL]; PPARG protein promotes the reaction [Niacin results in increased expression of ABCA1 mRNA]
CTD PMID:15037193, PMID:18602814, PMID:19797938, PMID:19878707, PMID:20303128, PMID:20448206, PMID:20655299 NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 decreases expression
multiple interactions
increases expression
EXP
ISO
Niacin results in decreased expression of ABCG1 protein
[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol; ABCG1 protein promotes the reaction [Niacin results in increased export of Cholesterol, HDL]; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol]
CTD PMID:19878707, PMID:20448206, PMID:21317532 NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
JBrowse link
G Ace angiotensin I converting enzyme decreases activity EXP Niacin results in decreased activity of ACE protein CTD PMID:18374418 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Acmsd aminocarboxymuconate semialdehyde decarboxylase affects abundance
multiple interactions
EXP ACMSD protein affects the abundance of Niacin
[Diethylhexyl Phthalate results in decreased activity of ACMSD protein] which results in increased abundance of Niacin; Dibutyl Phthalate affects the reaction [ACMSD protein affects the abundance of Niacin]
CTD PMID:12036039 NCBI chr13:44,424,689...44,468,734
Ensembl chr13:44,424,689...44,468,734
JBrowse link
G Adam17 ADAM metallopeptidase domain 17 increases expression EXP Niacin results in increased expression of ADAM17 protein CTD PMID:19223914 NCBI chr 6:43,400,525...43,448,280
Ensembl chr 6:43,400,528...43,448,280
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases expression
multiple interactions
ISO
EXP
Niacin results in increased expression of ADIPOQ mRNA; Niacin results in increased expression of ADIPOQ protein
HCAR2 protein promotes the reaction [Niacin results in increased expression of ADIPOQ protein]
Niacin promotes the reaction [ADIPOQ protein binds to ADIPOQ protein]
CTD PMID:16887123, PMID:16979396, PMID:17996241, PMID:18249215, PMID:19131065, PMID:19141678, PMID:21236357 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
JBrowse link
G Agt angiotensinogen multiple interactions
decreases expression
ISO
EXP
Niacin inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species]
Niacin results in decreased expression of AGT protein
CTD PMID:18374418, PMID:18550065 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Ahsg alpha-2-HS-glycoprotein multiple interactions ISO Niacin results in decreased expression of and results in decreased phosphorylation of AHSG protein CTD PMID:19405044 NCBI chr11:81,711,269...81,717,594 JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP [Niacin co-treated with Chromium] results in increased phosphorylation of AKT1 protein CTD PMID:19027847 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Angpt1 angiopoietin 1 increases expression ISO
EXP
Niacin results in increased expression of ANGPT1 mRNA CTD PMID:17557352 NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
JBrowse link
G Angpt2 angiopoietin 2 decreases expression ISO Niacin results in decreased expression of ANGPT2 mRNA CTD PMID:17557352 NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195
JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions
increases expression
ISO [Chromium co-treated with Niacin] results in increased expression of APOA1 mRNA; [Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein; [Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Niacin promotes the reaction [Rosuvastatin Calcium results in increased expression of APOA1 protein]
2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]
Niacin results in increased expression of APOA1 protein
CTD PMID:11701466, PMID:12633795, PMID:12767421, PMID:15539964, PMID:17319473, PMID:18420099, PMID:18566298, PMID:18602814, PMID:19797938, PMID:20152243 NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
JBrowse link
G Apob apolipoprotein B multiple interactions
decreases expression
ISO [Niacin co-treated with Lovastatin] results in decreased expression of APOB protein; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein
Niacin results in decreased expression of APOB protein
CTD PMID:11701466, PMID:12633795, PMID:15539964, PMID:18471454 NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
JBrowse link
G Arhgap8 Rho GTPase activating protein 8 increases expression EXP Niacin results in increased expression of ARHGAP8 mRNA CTD PMID:20303128 NCBI chr 7:125,732,300...125,797,149
Ensembl chr 7:125,731,275...125,795,980
JBrowse link
G Asph aspartate-beta-hydroxylase multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ASPH mRNA] CTD PMID:16940432 NCBI chr 5:22,577,680...22,799,333
Ensembl chr 5:22,577,675...22,799,349
JBrowse link
G Atp5f1b ATP synthase F1 subunit beta decreases expression ISO Niacin results in decreased expression of ATP5F1B protein CTD PMID:18316796 NCBI chr 7:2,504,708...2,511,748
Ensembl chr 7:2,504,695...2,511,749
JBrowse link
G Bdnf brain-derived neurotrophic factor increases expression EXP Niacin results in increased expression of BDNF protein CTD PMID:20671245 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Btc betacellulin multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of BTC mRNA] CTD PMID:16940432 NCBI chr14:18,231,854...18,270,621
Ensembl chr14:18,231,860...18,272,484
JBrowse link
G Casq1 calsequestrin 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of CASQ1 mRNA] CTD PMID:16940432 NCBI chr13:90,592,676...90,602,365
Ensembl chr13:90,592,681...90,602,365
JBrowse link
G Cat catalase multiple interactions
increases expression
EXP [Niacin co-treated with Chromium] results in increased activity of CAT protein
Niacin results in increased expression of CAT protein
CTD PMID:16931439, PMID:19420110 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cav1 caveolin 1 multiple interactions EXP [Niacin co-treated with Chromium] inhibits the reaction [CAV1 protein binds to NOS3 protein]; [Niacin co-treated with Chromium] results in decreased expression of CAV1 protein CTD PMID:19027847 NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
JBrowse link
G Cav3 caveolin 3 multiple interactions EXP [Niacin co-treated with Chromium] promotes the reaction [SLC2A4 protein binds to CAV3 protein]; [Niacin co-treated with Chromium] results in increased expression of CAV3 protein CTD PMID:19027847 NCBI chr 4:144,382,945...144,398,919
Ensembl chr 4:144,382,945...144,398,917
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression
multiple interactions
ISO
EXP
Niacin results in decreased expression of CCL2 protein
Niacin inhibits the reaction [TNF protein results in increased expression of CCL2 protein]
CTD PMID:18550065, PMID:19420110 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Cd36 CD36 molecule increases expression
decreases expression
ISO
EXP
Niacin results in increased expression of CD36 mRNA
Niacin results in decreased expression of CD36 protein
CTD PMID:19878707, PMID:24767308 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
EXP Etoposide promotes the reaction [Niacin deficiency results in increased expression of CDKN1A protein] CTD PMID:17516866 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha increases expression ISO Niacin results in increased expression of CEBPA mRNA CTD PMID:19131065 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
decreases expression
ISO [Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]] which results in decreased expression of PTGS2 mRNA; Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]
Niacin results in decreased expression of CEBPB mRNA; Niacin results in decreased expression of CEBPB protein
CTD PMID:21236357 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression ISO Niacin results in increased expression of CEBPD mRNA CTD PMID:19131065 NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
JBrowse link
G Cert1 ceramide transporter 1 multiple interactions ISO [Niacin results in decreased expression of and results in decreased activity of CERT1 protein] which results in increased abundance of Cholesterol, HDL; Niacin results in decreased expression of and results in decreased activity of CERT1 protein CTD PMID:18669886 NCBI chr 2:27,365,145...27,469,797
Ensembl chr 2:27,365,148...27,469,779
JBrowse link
G Chn2 chimerin 2 increases expression EXP Niacin results in increased expression of CHN2 mRNA CTD PMID:20303128 NCBI chr 4:84,423,708...84,452,989
Ensembl chr 4:84,194,347...84,454,500
JBrowse link
G Cidea cell death-inducing DFFA-like effector a multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of CIDEA mRNA] CTD PMID:16940432 NCBI chr18:63,082,861...63,108,450
Ensembl chr18:63,098,144...63,108,051
JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 decreases expression ISO Niacin results in decreased expression of CPT2 mRNA CTD PMID:19131065 NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
JBrowse link
G Crp C-reactive protein multiple interactions
decreases expression
ISO [resveratrol co-treated with pterostilbene co-treated with Quercetin co-treated with tocotrienol, delta co-treated with Niacin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein] CTD PMID:16950175, PMID:18420099, PMID:24319627 NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
JBrowse link
G Cst11 cystatin 11 increases expression EXP Niacin results in increased expression of CST11 mRNA CTD PMID:20303128 NCBI chr 3:143,096,056...143,098,780
Ensembl chr 3:143,096,056...143,098,780
JBrowse link
G Cst8 cystatin 8 increases expression EXP Niacin results in increased expression of CST8 mRNA CTD PMID:20303128 NCBI chr 3:143,129,240...143,141,000
Ensembl chr 3:143,129,248...143,156,177
JBrowse link
G Cyba cytochrome b-245 alpha chain decreases expression EXP Niacin results in decreased expression of CYBA protein CTD PMID:19420110 NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
JBrowse link
G Ddhd1 DDHD domain containing 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of DDHD1 mRNA] CTD PMID:16940432 NCBI chr15:19,963,639...20,032,263
Ensembl chr15:19,965,187...20,032,191
JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 multiple interactions
decreases activity
ISO [Niacin results in decreased activity of DGAT2 protein] which results in decreased chemical synthesis of Triglycerides CTD PMID:15258194 NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
JBrowse link
G Dusp5 dual specificity phosphatase 5 increases expression EXP Niacin results in increased expression of DUSP5 mRNA CTD PMID:20303128 NCBI chr 1:274,245,184...274,258,595
Ensembl chr 1:274,245,184...274,258,595
JBrowse link
G Ecel1 endothelin converting enzyme-like 1 increases expression EXP Niacin results in increased expression of ECEL1 mRNA CTD PMID:20303128 NCBI chr 9:94,238,568...94,252,484
Ensembl chr 9:94,239,006...94,250,809
JBrowse link
G Ednrb endothelin receptor type B multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of EDNRB mRNA] CTD PMID:16940432 NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
JBrowse link
G Egr2 early growth response 2 increases expression EXP Niacin results in increased expression of EGR2 mRNA CTD PMID:20303128 NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A increases phosphorylation EXP Niacin results in increased phosphorylation of EIF2A protein CTD PMID:12837665 NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions EXP Niacin results in decreased phosphorylation of and results in decreased activity of EIF4EBP1 protein CTD PMID:12837665 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Eno3 enolase 3 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ENO3 mRNA] CTD PMID:16940432 NCBI chr10:57,278,271...57,283,661
Ensembl chr10:57,278,307...57,283,653
JBrowse link
G F2r coagulation factor II (thrombin) receptor increases expression ISO Niacin results in increased expression of F2R protein CTD PMID:20539903 NCBI chr 2:26,118,760...26,135,340
Ensembl chr 2:26,118,760...26,135,340
JBrowse link
G Fabp1 fatty acid binding protein 1 increases expression EXP Niacin results in increased expression of FABP1 protein CTD PMID:19878707 NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO [Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 protein; fluprostenol inhibits the reaction [Niacin results in increased expression of FABP4 mRNA] CTD PMID:21236357 NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
JBrowse link
G Fasn fatty acid synthase decreases expression ISO Niacin results in decreased expression of FASN mRNA CTD PMID:19131065 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Foxo1 forkhead box O1 multiple interactions EXP Niacin results in decreased phosphorylation of and results in increased activity of FOXO1 protein CTD PMID:20303128 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Gcg glucagon multiple interactions ISO [Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GCG protein; Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GCG protein] CTD PMID:838844 NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
JBrowse link
G Ggt1 gamma-glutamyltransferase 1 increases expression EXP Niacin results in increased expression of GGT1 mRNA CTD PMID:20303128 NCBI chr20:14,019,723...14,045,781
Ensembl chr20:14,019,723...14,025,068
JBrowse link
G Gh1 growth hormone 1 multiple interactions ISO [Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GH1 protein; Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GH1 protein] CTD PMID:838844 NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 multiple interactions ISO [INS1 protein co-treated with Niacin] results in increased activity of GPD1 protein CTD PMID:2523799 NCBI chr 7:141,368,928...141,377,931
Ensembl chr 7:141,370,491...141,377,928
JBrowse link
G Gpi glucose-6-phosphate isomerase multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of GPI1 mRNA] CTD PMID:16940432 NCBI chr 1:90,063,411...90,091,287
Ensembl chr 1:90,063,411...90,091,287
JBrowse link
G Hcar2 hydroxycarboxylic acid receptor 2 multiple interactions
increases response to substance
affects activity
affects binding
increases activity
ISO
EXP
[Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK1 protein; [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK3 protein; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; HCAR2 protein promotes the reaction [Niacin results in increased expression of and results in increased activity of PPARG protein]; Niacin binds to and affects the activity of HCAR2 protein; Niacin binds to and results in increased activity of HCAR2 protein
HCAR2 protein results in increased susceptibility to Niacin
[[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [HCAR2 protein results in increased susceptibility to Niacin] which results in increased abundance of Dinoprostone; [HCAR2 protein results in increased susceptibility to Niacin] which results in increased abundance of Prostaglandin D2; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Cyclic AMP; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Fatty Acids, Nonesterified; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Triglycerides; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol]; HCAR2 protein promotes the reaction [Niacin results in decreased abundance of Fatty Acids]; HCAR2 protein promotes the reaction [Niacin results in increased expression of ADIPOQ protein]; Niacin binds to and results in increased activity of HCAR2 protein
Niacin affects the activity of HCAR2 protein
[Niacin analog binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Fatty Acids, Nonesterified; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Fatty Acids, Nonesterified; Niacin binds to and results in increased activity of HCAR2 protein
Niacin binds to HCAR2 protein
CTD PMID:12563315, PMID:15929991, PMID:16018973, PMID:16099840, PMID:16322797, PMID:16386710, PMID:16389067, PMID:17804224, PMID:18722346, PMID:19141678, PMID:19223991, PMID:19309152, PMID:20380810, PMID:20452209, PMID:20460384, PMID:20655299, PMID:21167710, PMID:21317532 NCBI chr12:38,160,464...38,161,546
Ensembl chr12:38,160,464...38,161,546
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases expression EXP Niacin results in decreased expression of HIF1A protein CTD PMID:18549825 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [[Niacin binds to Chromium] which co-treated with Cardiotonic Agents] results in increased expression of HMOX1 protein CTD PMID:16840737 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 multiple interactions EXP [[Niacin binds to Chromium] which co-treated with Cardiotonic Agents] results in increased expression of HSPB1 protein CTD PMID:16840737 NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression
ISO
EXP
Niacin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; Niacin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Niacin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]
[Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of ICAM1 mRNA]; [Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of ICAM1 protein]
Niacin results in decreased expression of ICAM1 protein
CTD PMID:16916501, PMID:18622720, PMID:19159436 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Ifng interferon gamma multiple interactions ISO Niacin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] CTD PMID:19159436 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of IL1B protein]; Niacin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein] CTD PMID:17516992, PMID:19159436 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions EXP
ISO
Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 mRNA]; Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]
[Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of IL6 protein]
CTD PMID:17516992, PMID:20975550 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Kdr kinase insert domain receptor increases expression ISO Niacin results in increased expression of KDR mRNA CTD PMID:17557352 NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
JBrowse link
G Kras KRAS proto-oncogene, GTPase affects localization ISO Niacin affects the localization of KRAS protein CTD PMID:12106604 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Lep leptin increases expression ISO Niacin results in increased expression of LEP protein
Niacin results in increased expression of LEP mRNA
CTD PMID:16887123, PMID:21236357 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Lepr leptin receptor multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of BTC mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of CIDEA mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of DDHD1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of NET1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of PCK1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of TTPA mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of UCP1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ASPH mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of CASQ1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of EDNRB mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ENO3 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of GPI1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of NRAP mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of PI16 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of RALGAPA1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of SRL mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TLN1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TPM1 mRNA] CTD PMID:16940432 NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
JBrowse link
G Lipe lipase E, hormone sensitive type decreases activity
decreases expression
ISO Niacin results in decreased activity of LIPE protein
Niacin results in decreased expression of LIPE mRNA
CTD PMID:14749208, PMID:19131065 NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor increases expression EXP Niacin results in increased expression of LITAF mRNA CTD PMID:20303128 NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
JBrowse link
G Map2 microtubule-associated protein 2 increases expression EXP Niacin results in increased expression of MAP2 mRNA CTD PMID:20303128 NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK1 protein; [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK1 protein; Pertussis Toxin inhibits the reaction [Niacin results in increased phosphorylation of MAPK1 protein] CTD PMID:16389067 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK3 protein; [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK3 protein; Pertussis Toxin inhibits the reaction [Niacin results in increased phosphorylation of MAPK3 protein] CTD PMID:16389067 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mlxipl MLX interacting protein-like decreases expression EXP Niacin results in decreased expression of MLXIPL protein CTD PMID:19878707 NCBI chr12:24,590,645...24,619,639 JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions EXP Niacin results in decreased phosphorylation of and results in decreased activity of MTOR protein CTD PMID:12837665 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Ncf1 neutrophil cytosolic factor 1 decreases expression EXP Niacin results in decreased expression of NCF1 protein CTD PMID:19420110 NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
JBrowse link
G Net1 neuroepithelial cell transforming 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of NET1 mRNA] CTD PMID:16940432 NCBI chr17:69,991,786...70,020,977
Ensembl chr17:70,010,794...70,020,982
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases expression EXP Niacin results in decreased expression of NFKB1 protein CTD PMID:19420110 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions EXP Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of NFKBIA protein]; Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased phosphorylation of NFKBIA protein] CTD PMID:20975550 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP Niacin inhibits the reaction [Silicon Dioxide results in increased expression of and results in increased activity of NOS2 protein] CTD PMID:15182488 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nos3 nitric oxide synthase 3 increases expression
increases phosphorylation
multiple interactions
ISO
EXP
Niacin results in increased expression of NOS3 mRNA
Niacin results in increased phosphorylation of NOS3 protein
[Niacin co-treated with Chromium] inhibits the reaction [CAV1 protein binds to NOS3 protein]; [Niacin co-treated with Chromium] results in increased phosphorylation of NOS3 protein
CTD PMID:17557352, PMID:19027847 NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
JBrowse link
G Notch1 notch receptor 1 increases expression EXP Niacin results in increased expression of NOTCH1 protein CTD PMID:19223914 NCBI chr 3:3,905,562...3,951,015
Ensembl chr 3:3,905,453...3,951,025
JBrowse link
G Nox4 NADPH oxidase 4 decreases expression EXP Niacin results in decreased expression of NOX4 protein CTD PMID:19420110 NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 increases expression
multiple interactions
ISO Niacin results in increased expression of NR1H3 mRNA
PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]
2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin results in increased expression of NR1H3 mRNA]; PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]
CTD PMID:15037193, PMID:19797938 NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
JBrowse link
G Nrap nebulin-related anchoring protein multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of NRAP mRNA] CTD PMID:16940432 NCBI chr 1:277,104,519...277,181,397
Ensembl chr 1:277,104,514...277,181,414
JBrowse link
G Ntrk2 neurotrophic receptor tyrosine kinase 2 increases expression EXP Niacin results in increased expression of NTRK2 protein CTD PMID:20671245 NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
JBrowse link
G Olr1 oxidized low density lipoprotein receptor 1 multiple interactions EXP [Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of OLR1 mRNA]; [Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of OLR1 protein] CTD PMID:18622720 NCBI chr 4:163,239,853...163,261,937
Ensembl chr 4:163,239,849...163,261,958
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO
EXP
[Niacin co-treated with Ubiquinone co-treated with Riboflavin] results in increased expression of PARP1 protein
Niacin deficiency affects the reaction [Etoposide results in increased cleavage of PARP1 protein]
CTD PMID:17516866, PMID:18377693 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 decreases expression
multiple interactions
EXP
ISO
Niacin results in decreased expression of PCK1 mRNA
LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of PCK1 mRNA]
CTD PMID:16940432, PMID:20303128 NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 increases expression EXP Niacin results in increased expression of PDK4 mRNA CTD PMID:20303128 NCBI chr 4:30,546,772...30,556,774
Ensembl chr 4:30,546,664...30,556,814
JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions
decreases expression
ISO Niacin inhibits the reaction [TNF protein results in increased expression of PECAM1 protein]
Niacin results in decreased expression of PECAM1 protein
CTD PMID:19159436 NCBI chr10:94,850,971...94,913,202 JBrowse link
G Pi16 peptidase inhibitor 16 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of PI16 mRNA] CTD PMID:16940432 NCBI chr20:6,923,176...6,932,786
Ensembl chr20:6,923,489...6,932,786
JBrowse link
G Pla2g7 phospholipase A2 group VII decreases expression ISO Niacin results in decreased expression of PLA2G7 protein CTD PMID:16950175 NCBI chr 9:19,935,754...19,978,013
Ensembl chr 9:19,935,768...19,978,013
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression EXP
ISO
Niacin results in increased expression of PPARA protein
Niacin results in increased expression of PPARA mRNA
CTD PMID:18602814, PMID:19878707, PMID:24767308 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO 4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine inhibits the reaction [Niacin results in increased activity of PPARG protein]; Aspirin inhibits the reaction [Niacin results in increased activity of PPARG protein]; HCAR2 protein promotes the reaction [Niacin results in increased expression of and results in increased activity of PPARG protein]; HCAR3 protein promotes the reaction [Niacin results in increased activity of PPARG protein]; Niacin results in increased expression of and results in increased activity of PPARG protein; PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]; PTGDS protein promotes the reaction [Niacin results in increased activity of PPARG protein]; PTGS1 protein promotes the reaction [Niacin results in increased activity of PPARG protein]
Niacin results in increased expression of PPARG mRNA
[Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG protein; fluprostenol inhibits the reaction [Niacin results in increased expression of PPARG mRNA]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; PPARG protein promotes the reaction [Niacin results in increased expression of ABCA1 mRNA]; PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]
CTD PMID:15037193, PMID:16386710, PMID:19131065, PMID:19797938, PMID:21236357, PMID:24767308 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression ISO Niacin results in increased expression of PPARGC1A mRNA CTD PMID:23056435 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 increases activity ISO Niacin results in increased activity of PRKAA2 protein CTD PMID:14749208 NCBI chr 5:124,568,845...124,642,569
Ensembl chr 5:124,574,079...124,642,569
JBrowse link
G Ptgdr prostaglandin D2 receptor multiple interactions ISO [MK-0524 binds to and results in decreased activity of PTGDR protein] which results in decreased susceptibility to Niacin CTD PMID:17392721 NCBI chr15:19,195,606...19,196,508 JBrowse link
G Ptgds prostaglandin D2 synthase multiple interactions ISO PTGDS protein promotes the reaction [Niacin results in increased activity of PPARG protein] CTD PMID:16386710 NCBI chr 3:2,686,125...2,689,059
Ensembl chr 3:2,686,123...2,689,084
JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions
decreases expression
increases response to substance
ISO
EXP
PTGS1 protein promotes the reaction [Niacin results in increased activity of PPARG protein]
Niacin results in decreased expression of PTGS1 protein
PTGS1 protein results in increased susceptibility to Niacin
CTD PMID:16322797, PMID:16386710, PMID:19420110 NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
decreases expression
ISO [Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]] which results in decreased expression of PTGS2 mRNA; [Niacin results in decreased expression of PTGS2 mRNA] which results in decreased abundance of Dinoprost; Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]
Niacin results in decreased expression of PTGS2 mRNA; Niacin results in decreased expression of PTGS2 protein
CTD PMID:21236357 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Qprt quinolinate phosphoribosyltransferase increases abundance EXP QPRT protein results in increased abundance of Niacin CTD PMID:11758903 NCBI chr 1:198,544,262...198,559,556
Ensembl chr 1:198,544,262...198,559,568
JBrowse link
G Ralgapa1 Ral GTPase activating protein catalytic subunit alpha 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of RALGAPA1 mRNA] CTD PMID:16940432 NCBI chr 6:76,386,971...76,661,530
Ensembl chr 6:76,396,784...76,608,864
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases expression
EXP
ISO
Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of and results in increased activity of RELA protein]
Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]
Niacin results in decreased expression of RELA protein
CTD PMID:18550065, PMID:19420110, PMID:20975550 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Retn resistin decreases expression ISO Niacin results in decreased expression of RETN protein CTD PMID:16979396 NCBI chr12:2,201,909...2,203,649
Ensembl chr12:2,201,891...2,204,249
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions EXP Niacin results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein CTD PMID:12837665 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Rtn4r reticulon 4 receptor decreases expression EXP Niacin results in decreased expression of RTN4R protein CTD PMID:20671245 NCBI chr11:86,992,665...87,017,091
Ensembl chr11:86,992,399...87,017,115
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions
decreases expression
increases expression
ISO
EXP
Aspirin inhibits the reaction [Niacin results in increased expression of SCARB1 mRNA]; Niacin promotes the reaction [SCARB1 protein results in increased export of Cholesterol, HDL]; Ro 31-8220 inhibits the reaction [Niacin results in increased expression of SCARB1 mRNA]
Niacin results in decreased expression of SCARB1 protein
CTD PMID:15037193, PMID:19878707, PMID:21291703 NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions
decreases expression
ISO
EXP
Niacin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]
Niacin results in decreased expression of SERPINE1 protein
CTD PMID:16916501, PMID:19420110 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Sirt2 sirtuin 2 increases expression ISO Niacin deficiency results in increased expression of SIRT2 mRNA CTD PMID:22860104 NCBI chr 1:86,948,866...86,971,954
Ensembl chr 1:86,948,918...86,971,952
JBrowse link
G Sirt4 sirtuin 4 increases expression ISO Niacin deficiency results in increased expression of SIRT4 mRNA CTD PMID:22860104 NCBI chr12:46,862,358...46,876,593
Ensembl chr12:46,868,416...46,876,592
JBrowse link
G Slc16a1 solute carrier family 16 member 1 increases import EXP SLC16A1 protein results in increased import of Niacin CTD PMID:10579682 NCBI chr 2:207,108,552...207,129,352
Ensembl chr 2:207,108,552...207,128,554
JBrowse link
G Slc22a7 solute carrier family 22 member 7 multiple interactions EXP
ISO
Niacin promotes the reaction [SLC22A7 protein results in increased export of Orotic Acid] CTD PMID:22981274 NCBI chr 9:16,925,321...16,931,119
Ensembl chr 9:16,924,520...16,931,766
JBrowse link
G Slc27a2 solute carrier family 27 member 2 increases expression ISO Niacin results in increased expression of SLC27A2 mRNA CTD PMID:24767308 NCBI chr 3:119,014,620...119,052,531
Ensembl chr 3:119,014,620...119,052,531
JBrowse link
G Slc27a4 solute carrier family 27 member 4 increases expression ISO Niacin results in increased expression of SLC27A4 mRNA CTD PMID:24767308 NCBI chr 3:8,363,937...8,376,858
Ensembl chr 3:8,363,937...8,376,858
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions EXP [Niacin co-treated with Chromium] promotes the reaction [SLC2A4 protein binds to CAV3 protein]; [Niacin co-treated with Chromium] results in increased localization of SLC2A4 protein CTD PMID:19027847 NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
JBrowse link
G Slc4a2 solute carrier family 4 member 2 increases uptake ISO SLC4A2 protein results in increased uptake of Niacin CTD PMID:9563070 NCBI chr 4:7,264,677...7,282,355
Ensembl chr 4:7,264,683...7,281,223
JBrowse link
G Spink5 serine peptidase inhibitor, Kazal type 5 increases expression EXP Niacin results in increased expression of SPINK5 mRNA CTD PMID:20303128 NCBI chr18:35,118,300...35,190,458
Ensembl chr18:35,121,967...35,191,069
Ensembl chr 1:35,121,967...35,191,069
JBrowse link
G Srl sarcalumenin multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of SRL mRNA] CTD PMID:16940432 NCBI chr10:11,240,135...11,284,325
Ensembl chr10:11,240,138...11,284,332
JBrowse link
G St6gal1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1 increases expression EXP Niacin results in increased expression of ST6GAL1 mRNA CTD PMID:20303128 NCBI chr11:80,927,601...80,981,424
Ensembl chr11:80,927,601...80,981,422
JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions EXP [[Niacin co-treated with Chromium] results in increased expression of STAR protein] which results in increased export of Cholesterol; [Niacin co-treated with Chromium] results in increased expression of STAR protein CTD PMID:17934701 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
JBrowse link
G Stat5a signal transducer and activator of transcription 5A decreases activity EXP Niacin results in decreased activity of STAT5A protein CTD PMID:15746188 NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
JBrowse link
G Syp synaptophysin increases expression EXP Niacin results in increased expression of SYP protein CTD PMID:20671245 NCBI chr  X:15,694,699...15,709,244
Ensembl chr  X:15,695,566...15,707,436
JBrowse link
G Tek TEK receptor tyrosine kinase increases expression
increases phosphorylation
EXP Niacin results in increased expression of TEK mRNA
Niacin results in increased phosphorylation of TEK protein
CTD PMID:17557352 NCBI chr 5:113,725,717...113,852,799
Ensembl chr 5:113,725,717...113,852,799
JBrowse link
G Tesc tescalcin increases expression EXP Niacin results in increased expression of TESC mRNA CTD PMID:20303128 NCBI chr12:44,141,258...44,174,701
Ensembl chr12:44,141,422...44,174,583
JBrowse link
G Tfrc transferrin receptor decreases expression EXP Niacin results in decreased expression of TFRC protein CTD PMID:18549825 NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression
ISO
EXP
Niacin inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 mRNA]; Niacin inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 protein]; Niacin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]
Niacin results in decreased expression of TGFB1 protein
CTD PMID:16916501, PMID:19337903, PMID:19420110 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tln1 talin 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TLN1 mRNA] CTD PMID:16940432 NCBI chr 5:59,033,635...59,063,592
Ensembl chr 5:59,033,636...59,063,592
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
[Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of TNF protein]; Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Niacin inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Niacin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Niacin inhibits the reaction [TNF protein results in increased expression of PECAM1 protein]; Niacin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]
Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA]; Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
CTD PMID:16916501, PMID:17516992, PMID:18550065, PMID:19159436, PMID:20975550 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 affects expression
decreases expression
multiple interactions
EXP Niacin deficiency affects the expression of TP53 protein
Niacin deficiency results in decreased expression of TP53 mRNA
Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein]
CTD PMID:17516866 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Tpm1 tropomyosin 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TPM1 mRNA] CTD PMID:16940432 NCBI chr 8:72,814,737...72,841,496
Ensembl chr 8:72,814,740...72,842,228
JBrowse link
G Ttpa alpha tocopherol transfer protein multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of TTPA mRNA] CTD PMID:16940432 NCBI chr 5:34,007,926...34,029,315
Ensembl chr 5:34,007,920...34,028,452
JBrowse link
G Ucp1 uncoupling protein 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of UCP1 mRNA] CTD PMID:16940432 NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO Niacin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA] CTD PMID:18550065 NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO
EXP
Niacin results in increased expression of VEGFA mRNA CTD PMID:17557352 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vtn vitronectin increases expression ISO Niacin results in increased expression of VTN protein CTD PMID:20539903 NCBI chr10:65,767,960...65,771,040
Ensembl chr10:65,767,053...65,771,038
JBrowse link
picloram term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Foxo1 forkhead box O1 decreases expression
multiple interactions
ISO Picloram results in decreased expression of FOXO1 mRNA
arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of FOXO1 mRNA]
CTD PMID:21318024 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 decreases expression
multiple interactions
ISO Picloram results in decreased expression of GRIN1 mRNA
arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of GRIN1 mRNA]
CTD PMID:21318024 NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
JBrowse link
G Mt-atp6 mitochondrially encoded ATP synthase membrane subunit 6 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of ATP6 mRNA] CTD PMID:21318024 NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599
JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I decreases expression
multiple interactions
ISO Picloram results in decreased expression of COX1 mRNA
arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of COX1 mRNA]
CTD PMID:21318024 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
JBrowse link
G Mt-cyb mitochondrially encoded cytochrome b multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of CYTB mRNA] CTD PMID:21318024 NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278
JBrowse link
G Mt-nd1 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of ND1 mRNA] CTD PMID:21318024 NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression ISO Picloram results in increased expression of PPARGC1A mRNA CTD PMID:21318024 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Prdx1 peroxiredoxin 1 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX1 mRNA] CTD PMID:21318024 NCBI chr 5:135,536,413...135,551,986
Ensembl chr 5:135,536,413...135,551,990
JBrowse link
G Prdx2 peroxiredoxin 2 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX2 mRNA] CTD PMID:21318024 NCBI chr19:26,084,816...26,090,095
Ensembl chr19:26,084,903...26,090,094
JBrowse link
G Prdx3 peroxiredoxin 3 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX3 mRNA] CTD PMID:21318024 NCBI chr 1:282,238,774...282,251,193
Ensembl chr 1:282,238,773...282,251,257
JBrowse link
G Prdx4 peroxiredoxin 4 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX4 mRNA] CTD PMID:21318024 NCBI chr  X:43,495,453...43,512,994
Ensembl chr  X:43,497,763...43,512,991
JBrowse link
G Prdx5 peroxiredoxin 5 decreases expression
multiple interactions
ISO Picloram results in decreased expression of PRDX5 mRNA
arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX5 mRNA]
CTD PMID:21318024 NCBI chr 1:222,164,462...222,167,447
Ensembl chr 1:222,164,462...222,167,447
JBrowse link
G Prdx6 peroxiredoxin 6 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX6 mRNA] CTD PMID:21318024 NCBI chr13:79,077,567...79,088,113
Ensembl chr13:79,077,033...79,088,127
JBrowse link
picolinic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 decreases expression ISO picolinic acid results in decreased expression of ABCA1 protein CTD PMID:16870493 NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions EXP [picolinic acid co-treated with Linoleic Acids, Conjugated] results in increased expression of ADIPOQ protein CTD PMID:17199723 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP picolinic acid inhibits the reaction [Cisplatin results in increased expression of BAX protein] CTD PMID:20817559 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Casp3 caspase 3 decreases activity
increases activity
ISO picolinic acid results in decreased activity of CASP3 protein
picolinic acid results in increased activity of CASP3 protein
CTD PMID:19853652 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO picolinic acid inhibits the reaction [Glucose results in increased secretion of CCL2 protein] CTD PMID:17665966 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Cd36 CD36 molecule affects localization ISO picolinic acid affects the localization of CD36 protein CTD PMID:20721637 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO ferrous sulfate inhibits the reaction [picolinic acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; picolinic acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CTD PMID:10799651, PMID:10823667 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 decreases glycation ISO picolinic acid results in decreased glycation of HBA1 protein CTD PMID:22944053 NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
JBrowse link
G Hspd1 heat shock protein family D (Hsp60) member 1 multiple interactions EXP picolinic acid inhibits the reaction [Cisplatin results in increased expression of HSPD1 protein] CTD PMID:20817559 NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions EXP picolinic acid promotes the reaction [INS1 protein results in increased expression of IGF1 mRNA] CTD PMID:20013160 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions EXP picolinic acid promotes the reaction [INS1 protein results in increased expression of IGF1R mRNA] CTD PMID:20013160 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Il6 interleukin 6 multiple interactions ISO picolinic acid inhibits the reaction [Glucose results in increased secretion of IL6 protein] CTD PMID:17665966 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Insr insulin receptor increases expression EXP picolinic acid results in increased expression of INSR mRNA CTD PMID:19283340 NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP picolinic acid inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 protein] CTD PMID:22790776 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions EXP picolinic acid inhibits the reaction [Streptozocin results in decreased expression of NFKBIA protein] CTD PMID:22790776 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Retn resistin decreases secretion ISO picolinic acid results in decreased secretion of RETN protein CTD PMID:19298540 NCBI chr12:2,201,909...2,203,649
Ensembl chr12:2,201,891...2,204,249
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions
affects localization
ISO [Glucose co-treated with picolinic acid] affects the localization of SLC2A4 protein
picolinic acid affects the localization of SLC2A4 protein
CTD PMID:16339278, PMID:16870493, PMID:19195868, PMID:20721637 NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 affects localization ISO picolinic acid affects the localization of SREBF1 protein CTD PMID:16870493 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP picolinic acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]; picolinic acid inhibits the reaction [Streptozocin results in increased secretion of TNF protein] CTD PMID:17854708, PMID:20817559 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Ubc ubiquitin C multiple interactions
decreases expression
EXP picolinic acid promotes the reaction [INS1 protein results in decreased expression of UBC mRNA]
picolinic acid results in decreased expression of UBC mRNA
CTD PMID:20013160 NCBI chr12:36,638,457...36,642,734
Ensembl chr12:36,638,457...36,642,734
JBrowse link
G Ucp3 uncoupling protein 3 increases expression EXP picolinic acid results in increased expression of UCP3 mRNA CTD PMID:19283340 NCBI chr 1:165,482,912...165,495,895
Ensembl chr 1:165,482,155...165,496,206
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    role 19732
      chemical role 19248
        donor 18377
          Bronsted acid 18240
            oxoacid 18192
              carbon oxoacid 18071
                carboxylic acid 18060
                  monocarboxylic acid 17406
                    pyridinemonocarboxylic acid 386
                      (5-bromo-3-pyridinyl)-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone 0
                      2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-5-(methoxymethyl)nicotinic acid + 2
                      2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)nicotinic acid + 1
                      2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                      2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                      2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-propylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-propylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide 0
                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-ethylisonicotinic acid 0
                      5-(2'-formylethyl)-4,6-dihydroxypicolinic acid 0
                      5-formyl-3-hydroxy-2-methylpyridine-4-carboxylic acid 0
                      5-methyl-2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]pyridine-3-carboxylic acid + 0
                      5-pyridoxic acid + 0
                      Isoniazid calcium pyruvate 0
                      LSM-11632 0
                      LSM-12915 0
                      LSM-14259 0
                      LSM-14448 0
                      LSM-14622 0
                      LSM-14627 0
                      LSM-8759 0
                      LSM-9231 0
                      LSM-9415 0
                      LSM-9543 0
                      N'-[(2-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide 0
                      N'-[(3-nitro-4-oxo-1-cyclohexa-2,5-dienylidene)methyl]-4-pyridinecarbohydrazide 0
                      N'-[(3-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide 0
                      N'-[(4-methoxy-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2-pyridinecarbohydrazide 0
                      N-(1-thiophen-2-ylethylideneamino)-4-pyridinecarboxamide 0
                      N-[(4-phenylmethoxyphenyl)methylideneamino]-1-(phenylmethyl)-4-pyridin-1-iumcarboxamide 0
                      N-[(4-tert-butylphenyl)methylideneamino]-2-pyridinecarboxamide 0
                      N-[(5-bromo-2-thiophenyl)methylideneamino]-2-pyridinecarboxamide 0
                      N-[(5-nitro-2-thiophenyl)methylideneamino]-2-pyridinecarboxamide 0
                      N-[1-(5-nitro-2-tetrazolyl)propan-2-ylideneamino]-4-pyridinecarboxamide 0
                      N-[[2-(1H-imidazol-2-yl)-1-phenylethylidene]amino]-4-pyridinecarboxamide 0
                      N-[[4-(4-fluoroanilino)-4-oxobutan-2-ylidene]amino]-2-pyridinecarboxamide 0
                      N-[[4-[(2-chloro-5-thiazolyl)methoxy]-3-methoxyphenyl]methylideneamino]-4-pyridinecarboxamide 0
                      [3-(2-furanyl)-5-(thiophen-2-ylmethylamino)-1,2,4-triazol-1-yl]-(3-pyridinyl)methanone 0
                      [4-[(3-bromophenyl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone 0
                      [4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone 0
                      [5-(4-bromophenyl)-3-(2-hydroxyphenyl)-3,4-dihydropyrazol-2-yl]-pyridin-4-ylmethanone 0
                      clitidine 0
                      clonixin 0
                      florpyrauxifen + 0
                      flunixin 1
                      furonazide 0
                      glyconiazide 0
                      halauxifen + 0
                      isonicotinic acid + 156
                      methaniazide 0
                      monoethyl malonate 0
                      nicotinic acid + 246
                      piberaline 0
                      picloram + 13
                      picolinic acid + 34
                      salinazid 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    p-block element atom 19670
                      carbon group element atom 19572
                        carbon atom 19561
                          organic molecular entity 19561
                            organic group 18493
                              organic divalent group 18486
                                organodiyl group 18486
                                  carbonyl group 18389
                                    carbonyl compound 18389
                                      carboxylic acid 18060
                                        monocarboxylic acid 17406
                                          pyridinemonocarboxylic acid 386
                                            (5-bromo-3-pyridinyl)-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone 0
                                            2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-5-(methoxymethyl)nicotinic acid + 2
                                            2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)nicotinic acid + 1
                                            2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                                            2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                                            2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                                            2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-propylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-propylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                            2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-ethylisonicotinic acid 0
                                            5-(2'-formylethyl)-4,6-dihydroxypicolinic acid 0
                                            5-formyl-3-hydroxy-2-methylpyridine-4-carboxylic acid 0
                                            5-methyl-2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]pyridine-3-carboxylic acid + 0
                                            5-pyridoxic acid + 0
                                            Isoniazid calcium pyruvate 0
                                            LSM-11632 0
                                            LSM-12915 0
                                            LSM-14259 0
                                            LSM-14448 0
                                            LSM-14622 0
                                            LSM-14627 0
                                            LSM-8759 0
                                            LSM-9231 0
                                            LSM-9415 0
                                            LSM-9543 0
                                            N'-[(2-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide 0
                                            N'-[(3-nitro-4-oxo-1-cyclohexa-2,5-dienylidene)methyl]-4-pyridinecarbohydrazide 0
                                            N'-[(3-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide 0
                                            N'-[(4-methoxy-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2-pyridinecarbohydrazide 0
                                            N-(1-thiophen-2-ylethylideneamino)-4-pyridinecarboxamide 0
                                            N-[(4-phenylmethoxyphenyl)methylideneamino]-1-(phenylmethyl)-4-pyridin-1-iumcarboxamide 0
                                            N-[(4-tert-butylphenyl)methylideneamino]-2-pyridinecarboxamide 0
                                            N-[(5-bromo-2-thiophenyl)methylideneamino]-2-pyridinecarboxamide 0
                                            N-[(5-nitro-2-thiophenyl)methylideneamino]-2-pyridinecarboxamide 0
                                            N-[1-(5-nitro-2-tetrazolyl)propan-2-ylideneamino]-4-pyridinecarboxamide 0
                                            N-[[2-(1H-imidazol-2-yl)-1-phenylethylidene]amino]-4-pyridinecarboxamide 0
                                            N-[[4-(4-fluoroanilino)-4-oxobutan-2-ylidene]amino]-2-pyridinecarboxamide 0
                                            N-[[4-[(2-chloro-5-thiazolyl)methoxy]-3-methoxyphenyl]methylideneamino]-4-pyridinecarboxamide 0
                                            [3-(2-furanyl)-5-(thiophen-2-ylmethylamino)-1,2,4-triazol-1-yl]-(3-pyridinyl)methanone 0
                                            [4-[(3-bromophenyl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone 0
                                            [4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone 0
                                            [5-(4-bromophenyl)-3-(2-hydroxyphenyl)-3,4-dihydropyrazol-2-yl]-pyridin-4-ylmethanone 0
                                            clitidine 0
                                            clonixin 0
                                            florpyrauxifen + 0
                                            flunixin 1
                                            furonazide 0
                                            glyconiazide 0
                                            halauxifen + 0
                                            isonicotinic acid + 156
                                            methaniazide 0
                                            monoethyl malonate 0
                                            nicotinic acid + 246
                                            piberaline 0
                                            picloram + 13
                                            picolinic acid + 34
                                            salinazid 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.